Literature DB >> 11391530

An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region.

M Sun1, J R Eshleman, L D Ferrell, G Jacobs, E C Sudilovsky, R Tuthill, M R Hussein, O Sudilovsky.   

Abstract

Loss of heterozygosity (LOH) of chromosome 1 has been suggested, by karyotyping, to be an initial episode in human hepatocarcinogenesis. However, this alteration has not yet been investigated in cirrhotic nodules (CNs) or dysplastic nodules (DNs). In an initial study from explanted or resected cirrhotic livers, LOH in 1p36-p32 was examined in 31 hepatocellular carcinomas (HCCs), 25 low-grade dysplastic nodules (LGDNs), and 24 high-grade dysplastic nodules (HGDNs). In HCCs, LOH was detected most frequently at loci D1S2843 (1p36.1) (28.6%), D1S513 (1p34.3) (29.2%), and MYCL1 (1p34.1) (28.6%). In HGDN and LGDN, LOH incidences at D1S513 were 11.1% and 13.6%, respectively. To further refine those results and to determine sequential relationships among CN, DN, and HCC, LOH was next studied in an additional 53 HCCs, 56 HGDNs, 30 LGDNs, and 215 CNs from 11 explanted human cirrhotic livers, including 30 "nodule-in-nodule" lesions. Seven markers between D1S2843 (1p36.12) and MYCL1 (1p34.1), and 1 each at D1S484 (1q24.1), IGF2R-3 (6q26), and TP53 (17p13.1) were used. LOH at D1S2843 and D1S513 was detected in HCCs (20.4% and 23.5%, respectively), HGDNs (7.7% and 18.5%), LGDNs (13.6% and 6.9%), and CNs surrounding either HCCs or DNs (7.4% and 8.3%). These results demonstrate that LOH at D1S2843 and D1S513 are early events in human liver carcinogenesis. Data from CN surrounding either HCCs or DN, and also nodule-in-nodule lesions, provide evidence supporting a CN-->DN-->HCC progression. Different deletion patterns from multiple HCCs and DNs suggest independent origins for carcinogenesis in the same individual.

Entities:  

Mesh:

Year:  2001        PMID: 11391530     DOI: 10.1053/jhep.2001.24751

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma.

Authors:  Wen-Hua Xiao; Wei-Wen Liu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 2.  ZAS: C2H2 zinc finger proteins involved in growth and development.

Authors:  Lai-Chu Wu
Journal:  Gene Expr       Date:  2002

Review 3.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

4.  Rare allelic imbalances, but no mutations of the PRDX1 gene in human hepatocellular carcinomas.

Authors:  J Gisin; A Perren; M Bawohl; W Jochum
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

5.  cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis.

Authors:  Robert A Anders; Lisa M Yerian; Maria Tretiakova; Jon M Davison; Richard J Quigg; Peter H Domer; Jamie Hoberg; John Hart
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

6.  Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma.

Authors:  Yi-Ran Cai; Li Gong; Xiao-Ying Teng; Hong-Tu Zhang; Cheng-Feng Wang; Guo-Lian Wei; Lei Guo; Fang Ding; Zhi-Hua Liu; Qin-Jing Pan; Qin Su
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 7.  Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Authors:  Carlo Bartolozzi; Laura Crocetti; Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Daniela Campani
Journal:  Eur Radiol       Date:  2007-02-16       Impact factor: 7.034

Review 8.  Identification of drivers from cancer genome diversity in hepatocellular carcinoma.

Authors:  Atsushi Takai; Hien T Dang; Xin W Wang
Journal:  Int J Mol Sci       Date:  2014-06-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.